Prokidney (PROK) Cash & Equivalents (2021 - 2026)

Prokidney (PROK) has 6 years of Cash & Equivalents data on file, last reported at $101.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $101.9 million, up 4.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.9 million (up 4.18% YoY), and the FY2025 annual result was $108.5 million, up 9.5% from the prior year.
• Cash & Equivalents fell to $101.9 million in Q1 2026 per PROK's latest filing, from $108.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $506.3 million in Q3 2022 and troughed at $60.6 million in Q4 2023.
• A 5-year average of $183.9 million and a median of $108.1 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 2284.73% in 2022, then sank 87.63% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $490.3 million in 2022, then slumped by 87.63% to $60.6 million in 2023, then surged by 63.43% to $99.1 million in 2024, then increased by 9.5% to $108.5 million in 2025, then declined by 6.12% to $101.9 million in 2026.
• Business Quant data shows PROK's Cash & Equivalents at $101.9 million in Q1 2026, $108.5 million in Q4 2025, and $95.3 million in Q3 2025.